| Protocol | Title |
|---|---|
| CALGB80101 | Phase III Intergroup Trial of Adjuvant Chemoradiation After Resection
of Gastric or Gastroesophageal Adenocarcinoma.
Activation Date: 19-dec-2002 |
| 80403 | Randomized Phase II Study of ECF-C, IC-C, or Folfox-C in Metastatic
Esophageal and GE Junction cancer
Activation Date: 27-mar-2007 |
| C80405 | A Phase III Trial of Irinotecan / 5-FU / Leucovorin or Oxaliplatin /
5-FU / Leucovorin with Bevacizumab, or Cetuximab (C225), or with the
Combination of Bevacizumab and Cetuximab for Patients with Untreated
Metastatic Adenocarcinoma of the Colon or Rectum
Activation Date: 22-sep-2005 Suspended: 06-jun-2008 |
| E2205 | A Phase II Study to Measure Response Rate and Toxicity of
Neo-adjuvant Chemoradiotherapy with Oxaliplatin (OX) and Infusional
5-Fluorouracil (5-FU) Plus Cetuximab Followed by Post-Operative
Docetaxel and Cetuximab in Patients with Operable Adenocarcinoma of
the Esophagus.
Activation Date: 10-jun-2008 ECOG Participants(requires Adobe Acrobat) |
| E3204 | Phase II Study of Preoperative Radiation with Concurrent
Capecitabine, Oxaliplatin and Bevacizumab Followed by Surgery and
Postoperative 5-FU, Leucovorin, Oxaliplatin (FOLFOX) and Bevacizumab
in Patients with Locally Advanced Rectal Cancer
Activation Date: 25-jul-2006 Suspended: 09-jan-2008 ECOG Participants(requires Adobe Acrobat) |
| E3205 | Phase II Trial of Cetuximab Plus Cisplatin, 5-Fluorouracil and
Radiation in Immunocompetent Patients with Anal Carcinoma
Activation Date: 19-jan-2007 ECOG Participants(requires Adobe Acrobat) |
| E4203 | Phase II Study of Treatment Selection Based Upon Tumor Thymidylate
Synthase Expression in Previously Untreated Patients with Metastatic
Colorectal Cancer
Activation Date: 14-jul-2005 Suspended: 06-may-2008 ECOG Participants(requires Adobe Acrobat) |
| E5202 | A Randomized Phase III Study Comparing 5-FU, Leucovorin and
Oxaliplatin versus 5-FU, Leucovorin, Oxaliplatin and Bevacizumab in
Patients with Stage II Colon Cancer at High Risk for Recurrence to
Determine Prospectively the Prognostic Value of Molecular Markers
Activation Date: 04-aug-2005 |
| E5204 | Intergroup Randomized Phase III Study of Postoperative Oxaliplatin,
5-Fluorouracil and Leucovorin vs Oxaliplatin, 5-Fluorouracil,
Leucovorin and Bevacizumab for Patients with Stage II or III Rectal
Cancer Receiving Preoperative Chemoradiation
Activation Date: 17-feb-2006 |
| N0147 | A Randomized Phase III Trial of Oxaliplatin (OXAL) Plus
5-Fluorouracil (5-FU)/Leucovorin (CF) with or without Cetuximab
(C225) after Curative Resection for Patients with Stage III Colon
Cancer
Activation Date: 10-feb-2004 Suspended: 06-jun-2008 |
| NSABPR04 | A Clinical Trial Comparing Preoperative Radiation Therapy and
Capecitabine with or without Oxaliplatin with Preoperative Radiation
Therapy and Continuous Intravenous Infusion of 5-Flourouracil with ot
without Oxaliplatin in the Treatment of Patients with Operable
Carcinoma of the Rectum
Activation Date: 23-jul-2004 |
| RTOG 0436 | A Phase III Trial Evaluating the Addition of Cetuximab to Paclitaxel,
Cisplatin and Radiation for Patients With Esophageal Cancer Who Are
Treated Without Surgery
Activation Date: 08-jul-2008 |
| S0518 | A Phase III Prospective Randomized Comparison of Depot Octreotide
Plus Interferon Alpha Versus Depot Octreotide Plus Bevacizumab (NSC
#704865) in Advanced, Poor Prognosis Carcinoid Patients
Activation Date: 10-dec-2007 |
| S0600 | Phase III Trial of Irinotecan-Based Chemotherapy Plus Cetuximab
(NSC-714692) with or without Bevacizumab (NSC-704865) as Second-Line
Therapy for Patients with Metastatic Colorectal Cancer who have
Progressed on Bevacizumab with Either FOLFOX, OPTIMOX, or XELOX
Activation Date: 22-jun-2007 Suspended: 06-jun-2008 |
All contents copyright © 1998 Eastern Cooperative Oncology Group.
All rights reserved.
Revised: 08/20/08